Galena Biopharma (GALE) Tops Q1 EPS by 1c

Galena Biopharma (NASDAQ: GALE) reported Q1 EPS of ($0.08), $0.01 better than the analyst estimate of ($0.09). Revenue for the quarter came in at $2.75 million versus the consensus estimate of $3.47 million.

For earnings history and earnings-related data on Galena Biopharma (GALE) click here.

You May Also Be Interested In

• Blackhawk Network (HAWK) Reports Q2 Loss of $0.07; Offers Guidance
• LogicBio Therapeutics (LOGC) Misses Q2 EPS by 10c
• Lument Finance Trust (LFT) Misses Q2 EPS by 17c